03.01.2024 14:56:41

IceCure Medical Publishes Mouse Study On ProSense That Boosts Immune Response Against Cancer

(RTTNews) - Provider of minimally-invasive cryoablation technology IceCure Medical Ltd. (ICCM) Wednesday announced the publication of a study titled 'Piezo1 facilitates optimal T cell activation during tumor challenge' in OncoImmunology journal.

The independent mouse model study, using ProSense demonstrated that cryoablation can activate the body's natural immune response by enhancing CD8+ T cells, an important arm of immune response.

The developer of ProSense said the data might produce anti-cancer benefits in humans beyond tumor destruction during cryoablation procedure.

Analysen zu Icecure Medical Ltd.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Icecure Medical Ltd. 1,24 0,00% Icecure Medical Ltd.